US Stock Insider Trading | Tandem Diabetes Care disclosed 14 insider transactions on February 19

2026-02-23 01:31:20

On February 19, 2026, Tandem Diabetes Care (TNDM) disclosed 14 insider transactions. Director Sheridan John F sold 2,400 shares on February 17, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 19, 2026	Executive	Carpenter Rick	February 17, 2026	Sell	1,312	18.95	$24,900
February 19, 2026	Executive	Vosseller Leigh	February 17, 2026	Sell	1,235	18.95	$23,400
February 19, 2026	Executive	Gasser Elizabeth Anne	February 17, 2026	Sell	1,534	18.95	$29,100
February 19, 2026	Director	Sheridan John F	February 17, 2026	Sell	4,363	18.95	$82,700
February 19, 2026	Executive	Morrison Susan	February 17, 2026	Sell	882	18.95	$16,700
February 19, 2026	Executive	Novara Mark David	February 17, 2026	Sell	62	18.95	$1,174.90
February 19, 2026	Executive	Hansen Shannon Marie	February 17, 2026	Sell	1,263	18.95	$23,900
January 20, 2026	Executive	Kyrillos Jean-Claude	January 15, 2026	Sell	2,118	21.07	$44,600
December 17, 2025	Executive	Novara Mark David	December 15, 2025	Sell	3,843	22.11	$85,000
December 17, 2025	Executive	Carpenter Rick	December 15, 2025	Sell	207	22.11	$4,576.77

[Company Information]

Tandem Diabetes Care, Inc. is a medical device company focused on designing, developing, and selling products for insulin-dependent diabetes patients. Tandem was originally founded on January 27, 2006, in Colorado, under the name Furey Company. To change the company name to Tandem Diabetes Care, it was reorganized in Delaware on January 7, 2008, and the company also relocated to Delaware. The company designs and sells its flagship product, the t:slim insulin infusion system, also called t:slim, developed based on proprietary technology platform and a unique customer-centric approach. The technology platform features patented microinfusion technology, a miniaturized pumping mechanism that draws insulin from a deformable bag placed inside the pump cover, eliminating the need for syringes and piston mechanisms. The system also includes user-friendly software architecture, a color touchscreen, a micro-USB port supporting charging and t:connect, and data management software. The company’s innovative approach to product design and development is customer-focused and market research-driven, as the company believes users are the primary decision-makers when purchasing insulin pens.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes